The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Open accessAbstract
IMPORTANCE: Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES: To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS: From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS: Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES: Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS: From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score-adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE: Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01014286.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 15 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2 or more genes, 24 (3%)”
- Also stated in: § Results · plain
“we found drivers in 2 genes in 24 tumors (3%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 190 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years (IQR, 1.96-7.70); the 248 with a driver and no targeted therapy, 2.5 years (P < .001”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ERBB2 (formerly HER2), 19 (3%)”
- Also stated in: § Results · plain
“The frequencies of ERBB2 (all exon 20 insertions) were 3% (19 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy”
- Also stated in: § Results · plain
“The 260 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ALK rearrangements, 57 (8%)”
- Also stated in: § Results · plain
“ALK rearrangements occurred in 57 of 733 specimens (8%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An oncogenic driver was found in 466 of 733 patients (64%).”
- Also stated in: § Results · plain
“Among the 733 specimens tested for all 10 genes, 466 (64% [95% CI, 60%-67%) had an oncogenic driver”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these 733 tumors, 182 tumors (25%) had the KRAS driver”
- Also stated in: § Results · plain
“KRAS mutations were the most frequent, found in 182 of 733 specimens (25%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 28% (95% CI, 24%-30%) of eligible patients and 44% of individuals with drivers detected received a targeted therapy.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequencies of drivers in the 1007 specimens in which at least 1 gene was assessed are presented in Table 2 and mirror the results with the patients’ tumors with full genotyping.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BRAF, 16 (2%)”
- Also stated in: § Results · plain
“BRAF mutations were 2% (16 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
- The quote only partly states this claim. 1
- It may state two separate claims as one. 8
- Probably not a substantial claim. 9
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“other EGFR, 29 (4%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC characterized at least 1 gene for 91% (1007 of 1102 patients) of eligible patients with genotyping of all 10 genes in 66% (733 of 1102 patients).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median potential follow-up was 2.0 years.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 938Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 175 patients (83%) with EGFR(s) mutations, 146 were treated with targeted therapy: 130 with erlotinib alone, and 16 with another EGFR inhibitor alone or in combination.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 175Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients in the driver + treatment group had a 5% better performance status, a 3-year lower median age, and were more likely to be never smokers (Table 1); factors that could lead to an improved prognosis.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Multiplexed testing aided physicians in selecting therapies.”
- Also stated in: § Conclusions · plain
“Multiplexed testing aided physicians in selecting therapies and patients for targeted trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Conclusions · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Testing for somatic mutations in the epidermal growth factor receptor (EGFR) gene4-6 and rearrangements of the anaplastic lymphoma kinase (ALK) gene7 is now routine.8”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [4] Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N Engl J Med 2004 350 21 2129 2139 15118073
- Not checked yetcites [5] Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 15118125
- Not checked yetcites [6] Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad SciUS A 2004 101 36 13306 13311 PMC516528 15329413
- Not checked yetcites [7] Kwak EL Bang YJ Camidge DR Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Engl J Med 2010 363 18 1693 1703 20979469 PMC3014291
- Not checked yetcites [8] National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology 2014 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 21
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adenocarcinoma was centrally confirmed.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Patients
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC clinical committee chairs reviewed the records of each patient with an oncogenic driver and the targeted agent administered to verify that the treatment was directed against that driver(s) detected in the patient’s tumor.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“With the proposed sample size of 1000, the half-width of the 95% CI is less than 5% if the oncogenic driver rate is less than 40%.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The decision to recommend a targeted therapy to a patient with a tumor harboring an oncogenic driver was left to the treating physician.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The knowledge-based confounding variables adjusted in the propensity model were sex, age at enrollment, performance status, smoking history, stage at diagnosis, prior therapy (surgery, chest radiotherapy, or chemotherapy), and elapsed time from metastatic disease diagnosis to study enrollment (years).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Criteria for specimen adequacy were not prespecified.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The LCMC effort differs from other genomic characterization efforts, like the Cancer Genome Atlas that studied patients with localized disease and obtained tissues exclusively from resection specimens.35-40”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
What the sources say
- Not checked yetcites [35] Weir BA Woo MS Getz G Characterizing the cancer genome in lung adenocarcinoma Nature 2007 450 7171 893 898 17982442 PMC2538683
- Not checked yetcites [36] Barletta JA Perner S Iafrate AJ Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma J Cell Mol Med 2009 13 8B 1977 1986 19040416 PMC2830395
- Not checked yetcites [37] Hammerman PS Sos ML Ramos AH Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 2011 1 1 78 89 22328973 PMC3274752
- Not checked yetcites [38] Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 7417 519 525 [published online September 27, 2012] 22960745 PMC3466113
- Not checked yetcites [39] D’Angelo SP Janjigian YY Ahye N Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 2012 7 12 1815 1822 23154553
- Not checked yetcites [40] Peifer M Fernández-Cuesta L Sos ML Integrative genome analyses identify key somatic driver mutations of small cell lung cancer Nat Genet 2012 44 10 1104 1110 22941188 PMC4915822
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC pathologists shared blinded samples, with a positive sample included for all 10 drivers.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The multiplexed genotyping platforms made effective use of patient tissue and identified actionable drivers sooner, giving patient’s earlier access to therapies or trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of EGFR mutations defines a specific molecular subgroup of NSCLC (~15% of Caucasian patients with adenocarcinomas) [37, 38] that respond to an EGFR TKI in over 60% of patients (Table 1).”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [38]
In the citing paper
“Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are detected in approximately 40% and 17% of lung adenocarcinoma in Asians1 and in Caucasians,2 respectively.”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
MET amplification count differs within the full-genotyping results
MajorMET amplification is reported in 5 of the 733 fully genotyped tumors, but the later count assigns MET amplification to 8 double-driver tumors in that group.
“Amplification of MET (MET/ CEP7 >2.2) was found in 5 of 733 patients’ tumors (<1%).”
“In the full genotyping group, we found drivers in 2 genes in 24 tumors (3%). Of these 24 specimens, 20 (83%) included either a mutation in PIK3CA (n = 12) or MET amplification (n = 8).”
Targeted-therapy percentage is overstated
MinorThe reported 275 of 1007 patients is 27.3%, which rounds to 27%, not 28%.
Reported 28 · recomputed 27.308838
“Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%).”
Supplementary figure number conflicts for the exclusion analysis
MinorThe Results attribute the analysis excluding EGFR- and ALK-positive cancers to eFigure 6, whereas the Discussion attributes that analysis to eFigure 4.
“We also recomputed the survival data excluding individuals with EGFR- and ALK-positive cancers. The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14; eFigure 6 in the Supplement).”
“survival analyses excluding these patients revealed that individuals with other drivers treated with targeted therapies still had an observed 2.5-year improvement in median survival over those who did not receive targeted therapy (eFigure 4 in the Supplement).”
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
METTL7B (methyltransferase-like 7B) identification as a novel biomarker for lung adenocarcinoma
Ali, J., Liu, W., Duan, W., Liu, C., Song, J., Ali, S., Li, E., & Wang, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4574 · Cited by 15
Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy
Marcu, L. G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040222 · Cited by 15
Song, Y., Du, J., Lu, P., Zou, Q., Zeng, S., Liu, M., Hu, X., Ma, W., Lin, H., Liu, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4995 · Cited by 15
Jiang, J., Zhao, C., Zhang, F., Liu, Z., Zhou, K., Ren, X., & Wan, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060782 · Cited by 17
Stratified Treatment in Lung Cancer
Michels, S. Y. F., & Wolf, J. (2016) · Oncology Research and Treatment · doi:10.1159/000453406 · Cited by 15
Personalized Medicine: The Future of Health Care
Meiliana, A., Dewi, N. M., & Wijaya, A. (2016) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v8i3.271 · Cited by 15
“Matching” consent to purpose: The example of the Matchmaker Exchange
Dyke, S. O. M., Knoppers, B. M., Hamosh, A., Firth, H. V., Hurles, M. E., Brudno, M., Boycott, K. M., Philippakis, A., & Rehm, H. L. (2017) · Human Mutation · doi:10.1002/humu.23278 · Cited by 15
McKeage, M. J., Elwood, M., Tin, S. T., Khwaounjoo, P., Aye, P. S., Li, A., Sheath, K. L., Shepherd, P., Laking, G. R., Kingston, N. J., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0515-4 · Cited by 16
Using Genomics to Guide Treatment for Glioblastoma
Young, J. S., Prados, M. D., & Butowski, N. A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0078 · Cited by 15
Moldaver, D., Hurry, M. V., Evans, W. K., Cheema, P. K., Sangha, R. S., Burkes, R. L., Melosky, B. L., Tran, D., Boehm, D., Venkatesh, J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.019 · Cited by 15
Zhao, S., Xian, X., Tian, P., Li, W., Wang, K., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633522 · Cited by 15
Bertaglia, V., Vallone, S., Pacchiana, M. V., & Novello, S. (2017) · Lung Cancer Management · doi:10.2217/lmt-2017-0011 · Cited by 14
Prager, G., Unseld, M., Waneck, F., Mader, R., Wrba, F., Raderer, M., Fuereder, T., Staber, P., Jäger, U., Kieler, M., et al. (2019) · OncoTarget · doi:10.18632/oncotarget.26604 · Cited by 14
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100390 · Cited by 14
Self-citationPredicting EGFR gene mutation status in lung adenocarcinoma based on multifeature fusion
Jiang, Y., Ma, S., Xiao, W. L., Wang, J., Ding, Y., Zheng, Y., & Sui, X. (2023) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2023.104786 · Cited by 17
Sumi, T., Yamada, Y., Koshino, Y., Watanabe, H., Nagayama, D., Michimata, H., Suzuki, K., Ikeda, T., Terai, K., Osuda, K., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.11.001 · Cited by 15
Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT
Yuan, L., An, L. K., Zhu, Y., Duan, C., Kong, W., Jiang, P., & Yu, Q. (2024) · Cancer Management and Research · doi:10.2147/cmar.s451871 · Cited by 16
In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy
Dipa, C. D., Hossain, S., Chy, M. M. K., Rahman, M. S. F., Kayes, T., Easha, A. M., Moin, A. T., Vakare, S. N., Patil, R. B., & Sarkar, B. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-10412-4 · Cited by 15
Suzawa, K., Yamamoto, H., Ohashi, K., Hashida, S., Tomida, S., Kubo, T., Maki, Y., Soh, J., Tsukuda, K., Kiura, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5567 · Cited by 14
Shepherd, P., Sheath, K. L., Tin, S. T., Khwaounjoo, P., Aye, P. S., Li, A., Laking, G. R., Kingston, N. J., Lewis, C. A., Elwood, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21023 · Cited by 14
Possible application of circulating free tumor DNA in non-small cell lung cancer patients
Karachaliou, N., Sosa, A. E., Molina‐Vila, M. Á., Ruiz, M. C., & Rosell, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.59 · Cited by 14
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V. D., Rosovsky, R. P. G., Lilenbaum, R., Bastos, B. R., Huang, C. H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.010 · Cited by 14
Self-citationDing, G., Wang, J., Ding, P., Wen, Y., & Yang, L. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1566049 · Cited by 14
Zhao, Z., Li, L., Wang, Z., Duan, J., Bai, H., & Wang, J. (2020) · Journal of Cancer · doi:10.7150/jca.38411 · Cited by 14
Tang, Y., Zhang, Y., & Wu, Z. (2020) · Medicine · doi:10.1097/md.0000000000019054 · Cited by 14
Perricos, A., Wenzl, R. J., Husslein, H., Eiwegger, T., Gstoettner, M., Weinhaeusel, A., Beikircher, G., & Kuessel, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062009 · Cited by 14
Nishimura, T., Nakamura, H., Yachie‐Kinoshita, A., Hase, T., Fujii, K., Koizumi, H., Naruki, S., Takagi, M., Matsuoka, Y., Furuya, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67894-7 · Cited by 14
Ohara, S., Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10020354 · Cited by 13
Huang, Y.-H., Hsu, K.-H., Chin, C.-S., Tseng, J., Yang, T., Chen, K., Su, K., Yu, S., Chen, J. J. W., & Chang, G. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.671 · Cited by 14
Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC
Liang, X., Lin, A., Wang, Q., Zhang, J., & Luo, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112909 · Cited by 14
Taniguchi, H., Akagi, K., Dotsu, Y., Yamada, T., Ono, S., Imamura, E., Gyotoku, H., Takemoto, S., Yamaguchi, H., Sen, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15579 · Cited by 13
The Minority Report: Targeting the Rare Oncogenes in NSCLC
McCoach, C. E., & Doebele, R. C. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0310-8 · Cited by 15
Tan, L., Alexander, M., Officer, A., MacManus, M. P., Mileshkin, L., Jennens, R. R., Herath, D., BOER, R. D., Fox, S. B., Ball, D., et al. (2017) · Internal Medicine Journal · doi:10.1111/imj.13491 · Cited by 14
Ku, B. M., Heo, M. H., Kim, J.-H., Cho, B. C., Cho, E. K., Min, Y. J., Lee, K. H., Sun, J., Lee, S., Ahn, J. S., et al. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2018.03.12 · Cited by 15
Kieler, M., Unseld, M., Bianconi, D., Waneck, F., Mader, R. M., Wrba, F., Fuereder, T., Marosi, C., Raderer, M., Staber, P. B., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000538 · Cited by 14
Yokouchi, H., Nishihara, H., Harada, T., Yamazaki, S., Kikuchi, H., Oizumi, S., Uramoto, H., Tanaka, F., Harada, M., Akie, K., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04439 · Cited by 13
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte, G., Passiglia, F., Galvano, A., & Russo, A. G. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1075000 · Cited by 14
Tumor Genetic Screening Programs: A Call to Action
Hyman, D. M., & Solit, D. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.9296 · Cited by 14
Fox, A. H., Osarogiagbon, R. U., Farjah, F., Jett, J. R., Johnson, B. E., Rivera, M. P., Smith, R. A., Wistuba, I. I., & Silvestri, G. A. (2024) · Cancer · doi:10.1002/cncr.34628 · Cited by 13
Self-citationMa, R., Yang, Q., Cao, S., Liu, S., Cao, H., Xu, H., Wu, J., & Feng, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239252 · Cited by 13
Han, J. M., Kim, S. M., Kim, H. L., Cho, H. J., & Jung, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119437 · Cited by 14
Molecular characteristics of gastric cancer with ERBB2 amplification
Cao, D., Xu, H., Li, L., Ju, Z., & Zhai, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18654 · Cited by 13
Reyes, A., Muddasani, R., & Massarelli, E. (2024) · Cancers · doi:10.3390/cancers16162919 · Cited by 14
Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency
Araujo, L. H., Timmers, C. D., Shilo, K., Zhao, W., Zhang, J., Yu, L., Natarajan, T. G., Miller, C. J., Yilmaz, A. S., Liu, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143092 · Cited by 13
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets
Drosten, M., & Barbacid, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1360-5 · Cited by 12
Russo, A., Franchina, T., Ricciardi, G. R. R., Fanizza, C., Scimone, A., Chiofalo, G., Giordano, A., & Adamo, V. (2017) · Oncotarget · doi:10.18632/oncotarget.14427 · Cited by 13
Rashdan, S., & Gerber, D. E. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.57 · Cited by 13
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Lazzari, C., Karachaliou, N., Gregorc, V., Bulotta, A., González‐Cao, M., Verlicchi, A., Altavilla, G., Rosell, R., & Santarpía, M. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1326822 · Cited by 13
Yao, Y., Peng, M., Shen, Q., Hu, Q., Gong, H., Li, Q., Zheng, Z., Xu, B., Li, Y., & Dong, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12932 · Cited by 13
Ao, L., Fang, S., Zhang, K., Gao, Y., Cui, J., Jia, W., Shan, Y., Zhang, J., Wang, G., Liu, J., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02369-3 · Cited by 13
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
Canale, M., Petracci, E., Cravero, P., Mariotti, M., Minuti, G., Metro, G., Ludovini, V., Baglivo, S., Puccetti, M., Dubini, A., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101471 · Cited by 16
Vatrano, S., Righi, L., Vavalà, T., Rapa, I., Busso, M., Izzo, S., Cappia, S., Veltri, A., Papotti, M., Scagliotti, G. V., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0383-8 · Cited by 14
Introduction to the Theme “Precision Medicine and Prediction in Pharmacology”
Insel, P. A., Amara, S. G., & Blaschke, T. F. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-101714-123102 · Cited by 13
Chiang, C., Wang, L., Ho, H., Tsai, C., Yeh, Y., Hsu, W., Chou, T., Chiu, C., & Wu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23686 · Cited by 13
Macrophage Origin, Metabolic Reprogramming and IL-1β Signaling: Promises and Pitfalls in Lung Cancer
Guilbaud, E., Gautier, E. L., & Yvan‐Charvet, L. (2019) · Cancers · doi:10.3390/cancers11030298 · Cited by 14
Xu, J., Yang, H., Jin, B., Lou, Y., Zhang, Y., Zhang, X., Zhong, H., Wang, H., Wu, D., & Han, B. (2016) · Scientific Reports · doi:10.1038/srep36371 · Cited by 13
Molecular Diagnostic Testing in Non-Small Cell Lung Cancer
Naidoo, J., & Drilon, A. E. D. C. (2014) · American Journal of Hematology / Oncology® · Cited by 13
Screening for Lung Cancer: What Comes Next?
Peled, N., & Ilouze, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1713 · Cited by 13
Adherence to Oral Targeted Anti-Lung Cancer Therapy: A Qualitative Interview Study
Zhou, H., Wang, X., Yu, D., Du, R., Wang, H., Zhu, J., Zhang, H., Chen, C., & Wang, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s341966 · Cited by 12
What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
Cui, R., Yang, Z., & Liu, L. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14620 · Cited by 11
Porta, C., Pradelli, L., Sicari, E., Castellani, S., Sivakumar, S., Sokol, E. S., Montesion, M., Wieland, T., Rambichler, J., Minari, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107359 · Cited by 12
Mosteiro, M., Azuara, D., Villatoro, S., Alay, A., Gausachs, M., Varela, M., Baixeras, N., Pijuán, L., Ajenjo-Bauza, M., López‐Doriga, A., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102197 · Cited by 12
Kolb, T., Müller, S., Möller, P., Barth, T. F. E., & Marienfeld, R. B. (2024) · Neoplasia · doi:10.1016/j.neo.2023.100955 · Cited by 12
Shi, Y., Li, C., Zhang, X., Peng, C., Sun, P., Zhang, Q., Wu, L., Ding, Y., Xie, D., Xu, Z., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae121 · Cited by 13
Tibau, A., Hwang, T. J., Avorn, J., & Kesselheim, A. S. (2024) · BMJ · doi:10.1136/bmj-2023-079126 · Cited by 13
Miyadera, K., Kakuto, S., Sugai, M., Tsugitomi, R., Amino, Y., Uchibori, K., Yanagitani, N., Sugiura, H., Seike, M., Nishio, M., et al. (2024) · Cancers · doi:10.3390/cancers16213712 · Cited by 15
González-Larriba, J. L., Lázaro-Quintela, M., Cobo, M., Dómine, M., Majem, M., & García‐Campelo, R. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.03 · Cited by 12
Kuo, C. S., Huang, C.-H., Liu, C., Pavlidis, S. P., Ko, H., Chung, F., Lin, T., Wang, C., Guo, Y., & Yang, C. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00657-1 · Cited by 12
Zhou, Y., Ge, F., Du, Y., Li, Q., Cai, J., Liu, X., Guo, Y., Shen, Z., Duan, L., Huang, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644895 · Cited by 12
Takeda, T., Yamada, T., Tanimura, K., Nakano, T., Ishida, M., Tachibana, Y., Shiotsu, S., Horiuchi, S., Hibino, M., Okada, A., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122170 · Cited by 12
Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
Liang, X., Zhang, W., Li, J., Zhu, J., Shao, J., Wang, J., Wu, H., Dai, J., Li, J., Xu, J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03952-z · Cited by 12
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
Bearz, A., Carlo, E. D., Conte, A. D., Spina, M., Ros, V. D., Bertoli, E., Revelant, A., Stanzione, B., & Tirelli, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137322 · Cited by 12
Zhang, L., You, Y., Liu, X., Liu, F., Nie, K., & Ji, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14880 · Cited by 12
Richards, C. E., Elamin, Y. Y., Carr, A., Gately, K. A., Rafee, S., Cremona, M., Hanrahan, E. O., Smyth, R., Ryan, D., Morgan, R. K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310545 · Cited by 13
RetractedMolecular Determinants of Radiation Response in Non–Small Cell Lung Cancer
Yom, S. S., Diehn, M., & Raben, D. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.12.007 · Cited by 12
Das fortgeschrittene Bronchialkarzinom – was gibt es Neues in der Diagnostik und Therapie?
Rothschild, S. I. (2015) · Praxis · doi:10.1024/1661-8157/a002058 · Cited by 12
Brčić, L., Jakopović, M., Mišić, M., Seiwerth, F., Kern, I., Smojver‐Ježek, S., Quehenberger, F., Samaržija, M., & Seiwerth, S. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0544-9 · Cited by 12
Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer
Rossi, A., Muscarella, L. A., Micco, C. D., Carbonelli, C. M., D’Alessandro, V., Notarangelo, S., Palomba, G., Sanpaolo, G., Taurchini, M., Graziano, P., et al. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1401064 · Cited by 12
Physician interpretation of genomic test results and treatment selection
Brusco, L., Wathoo, C., Shaw, K. R. M., Holla, V. R., Bailey, A. M., Johnson, A. M., Khotskaya, Y. B., Litzenburger, B. C., Sánchez, N., Zeng, J., et al. (2017) · Cancer · doi:10.1002/cncr.31112 · Cited by 12
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
Purim, O., Beny, A., Inbar, M., Shulman, K., Brenner, B., Dudnik, E., Bokstein, F., Temper, M., Limon, D., Matceyevsky, D., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0548-8 · Cited by 12
Planchard, D., & Johnson, B. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0088-ed · Cited by 12
Self-citationRotow, J. K., Woodard, G. A., Urisman, A., McCoach, C. E., Bivona, T. G., Elicker, B. M., Jablons, D. M., & Blakely, C. M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.003 · Cited by 12
Ono, A., Isaka, M., Serizawa, M., Omae, K., Kojima, H., Nakashima, K., Omori, S., Wakuda, K., Kenmotsu, H., Naito, T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.005 · Cited by 12
Ito, K., Nishio, M., Kato, M., Murakami, H., Aoyagi, Y., Ohe, Y., Okayama, T., Hashimoto, A., Ohsawa, H., Tanaka, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0645 · Cited by 12
Higo, H., Ohashi, K., Makimoto, G., Nishii, K., Kudo, K., Kayatani, H., Watanabe, H., Kano, H., Ninomiya, K., Hotta, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.019 · Cited by 15
Choi, Y., Kim, K., Jeong, B., Lee, K. J., Kim, H., Kwon, O. J., Kim, J., Choi, Y., Lee, H. Y., & Um, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1716 · Cited by 12
Iyoda, A., Azuma, Y., Sano, A., Sakai, T., Koezuka, S., Otsuka, H., Tochigi, N., Isobe, K., Sakamoto, S., & Takagi, K. (2021) · Journal of Bronchology & Interventional Pulmonology · doi:10.1097/lbr.0000000000000749 · Cited by 12
Goulart, B. H. L., Chennupati, S. R., Fedorenko, C. R., & Ramsey, S. D. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.019 · Cited by 12
The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer
Lengel, H. B., Connolly, J. G., Jones, G. D., Caso, R., Zhou, J. H., Sánchez-Vega, F., Mastrogiacomo, B., Isbell, J. M., Li, B. T., Liu, Y., et al. (2021) · Cancers · doi:10.3390/cancers13153656 · Cited by 12
Mitiushkina, N. V., Kholmatov, M. M., Venina, A. R., Tiurin, V. I., Yanus, G. A., Николаевна, С. Т., Yatsuk, O. S., Zaitseva, O. A., Ivantsov, A. O., Kuligina, E. S., et al. (2018) · Neoplasma · doi:10.4149/neo_2018_171225n843 · Cited by 11
Encorafenib and Binimetinib: A New Treatment Option for BRAFV600E-Mutant Non–Small-Cell Lung Cancer
Stinchcombe, T. E. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00983 · Cited by 12
Ellis, P. M., Long, L., Coschi, C. H., & Sathiyapalan, A. (2025) · Current Oncology · doi:10.3390/curroncol32110629 · Cited by 13
Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
Hu, Y. W., Ren, S., Yang, L., Tong, Z., Wang, R., Han, W., Zeng, C., Li, J., Xiao, P., Wang, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.912153 · Cited by 11
Nowak, P., Bil‐Lula, I., & Śliwińska‐Mossoń, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311206 · Cited by 11
The role of m6A methylation in targeted therapy resistance in lung cancer
Xue, H. (2024) · American Journal of Cancer Research · doi:10.62347/lxos2662 · Cited by 11
Oh, S. Y., Park, S., Lee, S.-Y., Lee, E. J., Kim, T. H., Choi, S., Park, S. Y., Kim, J. H., Lim, S. M., Lee, J. B., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101929 · Cited by 12
Programmed death‐ligand 1 immunohistochemistry testing for non‐small cell lung cancer in practice
Mino-Kenudson, M. A. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21873 · Cited by 11
Xu, C., Wang, W., Chen, Y., Chen, Y., Liu, W., Zhong, L., Chen, F., Zhuang, W., Song, Z., Chen, X.-H., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1468-9 · Cited by 11
Wu, Z., Zhang, Y., & Sun, H. (2020) · Medicine · doi:10.1097/md.0000000000018543 · Cited by 11
Lim, J. U., Yeo, C. D., Kim, H. W., Kang, H. S., Park, C. K., Kim, J. S., Kim, J. W., Kim, S. J., & Lee, S. H. (2020) · In Vivo · doi:10.21873/invivo.12027 · Cited by 11
Metadata
- Authors
- Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., Shyr, Y., Camidge, D. R., Sequist, L. V., Glisson, B. S., Khuri, F. R., Garon, E. B., Pao, W., Rudin, C., Schiller, J., Haura, E. B., Socinski, M., Shirai, K., Chen, H., Giaccone, G., Ladanyi, M., Kugler, K., Minna, J. D., & Bunn, P. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Vanderbilt University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Cancer Center Denver, Aurora
- University of Colorado Cancer Center (US)
- The Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts
- Winship Cancer Institute (US)
- University of California, Los Angeles (US)
- Johns Hopkins University (US)
- The University of Texas Southwestern Medical Center (US)
- Moffitt Cancer Center (US)
- UPMC Hillman Cancer Center (US)
- Medical University of South Carolina (US)
- National Institutes of Health (US)
- Corresponding author
- Kris, Mark G.
- ORCID
- Kris, Mark G.
- Johnson, Bruce E.
- Berry, Lynne D.
- Kwiatkowski, David J.
- Iafrate, A. John
- Wistuba, Ignacio I.
- Shyr, Yu
- Camidge, D. Ross
- Sequist, Lecia V.
- Glisson, Bonnie S.
- Khuri, Fadlo R.
- Garon, Edward B.
- Pao, William
- Rudin, Charles
- Schiller, Joan
- Haura, Eric B.
- Socinski, Mark
- Shirai, Keisuke
- Chen, Heidi
- Giaccone, Giuseppe
- Ladanyi, Marc
- Minna, John D.
- Bunn, Paul A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-21
- Volume
- 311
- Issue
- 19
- Pages
- 1998
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4163053
- OpenAlex
- W2065477010
- Semantic Scholar
- 07fff1c9d77fb2b8731d7d86b38c7ac05df654c7
- Cited by
- 1,724
- References
- 69
- Citations by year
- 2026: 55 · 2025: 99 · 2024: 101 · 2023: 116 · 2022: 164 · 2021: 171 · 2020: 173 · 2019: 137 · 2018: 186 · 2017: 162 · 2016: 173 · 2015: 146 · 2014: 37
- FWCI
- 138.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Cancer Institute (RC2CA148394, K23CA149079, P01CA129243, 1RC2CA148394‐010, P50CA058187, P30CA008748, P30CA016672, P30CA046934)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, oncogenic drivers, targeted therapy, multiplex genotyping, KRAS, EGFR, ALK rearrangement, BRAF, PIK3CA, ERBB2, MET amplification, NRAS, MEK1, AKT1, metastatic lung cancer, survival, genotype-directed therapy, clinical trial recruitment
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Proto-Oncogenes, Survival Analysis, Sequence Analysis, DNA, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Molecular Targeted Therapy, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
